CellMade Targets Inflammatory Biology Products and Services
19 March 2012: CellMade, Chappes, France: CellMade, a specialist provider of biomarker and drug discovery support for inflammation research, announces the launch of its new website. Reflecting the company’s leading position in using human cell-based technology to better inform research decisions, the new site features free poster and protocol downloads as well as updated information on the CellInsight™ platform and REACT-lipid™ service. www.cellmade.com looks set to become a primary resource for drug discovery and preclinical researchers working in inflammatory diseases.
Proprietary human primary co-culture models, primary human cells and stem cells, coupled with cytokine secretion assays and lipid bioanalysis, enables the CellMade team to identify and characterise the best biomarkers of early inflammatory response for drug discovery projects. These are critical tools to help companies to evaluate the safety and efficacy of their new drugs. In addition, the company uses its unique technology to develop companion tests for personalized medicine.
Ronald Bronsaer, Chief Executive Officer, CellMade said: “There is a growing need for effective companion tests for anti-inflammatory drugs, as patients and FDA concerns grow regarding the costs and unwanted side effects of the TNF-alpha antagonists. CellMade technology is being used to identify people who would benefit from such treatments, and to giving early warning signs of toxicity before clinical symptoms develop. The new website is a perfect vehicle to showcase our expertise and specialist knowledge in this area.”
To find out more, and to contact CellMade about a specific discovery project, visit: www.cellmade.com
High resolution image available from Claire England, Kapler Communications email@example.com Ref: CELL/JOB/001
CellMade is a specialized products and contract research services company providing biomarker and drug discovery support in the area of inflammation. The company has research facilities near Archamps, France (near Geneva) and on the Chemelot campus in Geleen, The Netherlands. The Company is headquartered in France.
The company’s human primary co-culture models, primary human cells and stem cells, coupled with cytokine secretion assays and lipid bioanalysis enable them to identify and characterise the best biomarkers of early inflammatory response for drug discovery projects. These are critical tools in helping client companies evaluate the safety and efficacy of their new drug candidates. CellMade’s unique technology is also used to develop companion tests for personalized medicine.
For press information, please contact:
Alexandra Jones, Kapler Communications
Phoenix House, Phoenix Park, Eaton Socon,
St Neots, Cambridgeshire PE19 8EP, UK
Tel: +44 (0)1480 471059; Fax: +44 (0)1480 471069 firstname.lastname@example.org
Ronald Bronsaer, Chief executive Officer, CellMade Head Office, 16 Rue de la CURE, 63720 CHAPPES, France. Tel. +33 (0) 4 50 43 84 91, email: email@example.com